Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Senti Biosciences is a clinical-stage biotechnology company developing cell and gene therapies for incurable diseases using its proprietary gene circuit platform. Their main products are off-the-shelf CAR-NK cell therapies, such as SENTI-202 for blood cancers and SENTI-301A for solid tumors, aiming to address unmet needs in oncology. The company is positioned as an innovator in engineered cell therapies with a focus on natural killer cells.
AI-generated summary. Not investment advice.